This product is a second-generation sulphonylurea hypoglycaemic agent.

It stimulates insulin secretion by pancreatic beta cells and enhances insulin release following glucose ingestion, thereby inhibiting hepatic gluconeogenesis and glucose output. This product reduces platelet stickiness and aggregation, accelerates fibrinolysis, and aids in the prevention and treatment of diabetic microvascular complications.

Primary Indications

For type II diabetes

The Main Contraindication To Medication

1. Contraindicated in patients with hepatic or renal impairment.

2. Contraindicated in patients with sulfonylurea allergy.

3. Contraindicated in patients with porphyria: may cause accumulation of porphyrin pigments in the body.

4. Contraindicated in patients undergoing treatment with miconazole.

Tablet